{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,18]],"date-time":"2026-01-18T01:09:35Z","timestamp":1768698575744,"version":"3.49.0"},"reference-count":26,"publisher":"FapUNIFESP (SciELO)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Rev. Assoc. Med. Bras."],"published-print":{"date-parts":[[2016,7]]},"abstract":"<jats:p>Summary Osteoporosis is a disease of ascending character in the world population; in this context, bone biomarkers are being increasingly studied in order to aid in the diagnosis and monitoring of these patients. The main objective of this study was a literature review of articles whose main theme was the use of biomarkers for bone formation and degradation, and to evaluate their possible applicability in clinical practice. Literature review was performed through articles indexed and published in the last five years in the PubMed database. The findings of this study showed that most of the previously selected articles were published in the last two years, and the most cited markers were bone resorption, C-terminal collagen telopeptide (CTX), showing the highest correlation with the dynamics of bone, and the biomarker of bone formation, bone-specific alkaline phosphatase (BAP), which is increased in the event of fracture or may suggest another bone disease. There was an increase in published articles, associating different bone biomarkers and their clinical applicability, especially for treatment control. Our findings suggest that in recent years there has been significant increase in publications evaluating the use of bone turnover biomarkers for bone formation and resorption and their possible clinical applicability, especially in the monitoring of treatment. Still, we believe that further studies need to be conducted to confirm these findings, given the advantages that bone biomarkers can deliver in the clinical management of the disease.<\/jats:p>","DOI":"10.1590\/1806-9282.62.04.368","type":"journal-article","created":{"date-parts":[[2016,7,16]],"date-time":"2016-07-16T13:34:55Z","timestamp":1468676095000},"page":"368-376","source":"Crossref","is-referenced-by-count":29,"title":["The use of biomarkers in clinical osteoporosis"],"prefix":"10.1590","volume":"62","author":[{"given":"Hebert Wilson Santos","family":"Cabral","sequence":"first","affiliation":[{"name":"Escola Superior de Ci\u00eancias da Santa Casa de Miseric\u00f3rdia de Vit\u00f3ria, Brazil; Escola Superior de Ci\u00eancias da Santa Casa de Miseric\u00f3rdia de Vit\u00f3ria, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruna Ferreira Galone","family":"Andolphi","sequence":"additional","affiliation":[{"name":"Emescam, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brunna Vila Coutinho","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Emescam, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle Cristina Filgueira","family":"Alves","sequence":"additional","affiliation":[{"name":"Emescam, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Renato L\u00edrio","family":"Morelato","sequence":"additional","affiliation":[{"name":"Emescam, Brazil; Emescam, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ant\u00f4nio","family":"Chambo Filho","sequence":"additional","affiliation":[{"name":"Emescam, Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liz\u00e2nia Spinass\u00e9","family":"Borges","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris Sud 11, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","reference":[{"issue":"3","key":"ref1","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1007\/s11914-009-0014-3","article-title":"Bone markers in osteoporosis","volume":"7","author":"Garnero P","year":"2009","journal-title":"Curr Osteoporos Rep"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1017\/S002966510800699X","article-title":"Biomarkers of bone health and osteoporosis risk","volume":"67","author":"Eastell R","year":"2008","journal-title":"Proc Nutr Soc"},{"issue":"suppl 2","key":"ref3","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1590\/S0034-89102009000900014","article-title":"Preval\u00eancia de diagn\u00f3stico auto-referido de osteoporose","volume":"43","author":"Martini LA","year":"2009","journal-title":"Rev Sa\u00fade P\u00fablica"},{"issue":"2","key":"ref4","first-page":"164","article-title":"Epidemiologia de fraturas pela osteoporose no Brasil: o que temos e o que precisamos","volume":"54","author":"Pinheiro MM","year":"2010","journal-title":"Arq Bras Endocrinol Metab"},{"key":"ref5","series-title":"Quedas de idosos. SUS gasta quase R$ 81 milh\u00f5es com fraturas em idosos em 2009","year":"2014"},{"issue":"7","key":"ref6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1590\/S0100-72032003000700007","article-title":"Preval\u00eancia de osteoporose em mulheres na p\u00f3s-menopausa e associa\u00e7\u00e3o com fatores cl\u00ednicos e reprodutivos","volume":"25","author":"Costa-Paiva L","year":"2003","journal-title":"Rev Bras Ginecol Obstet"},{"issue":"1","key":"ref7","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1210\/jc.2011-2081","article-title":"Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial","volume":"97","author":"Grey A","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"ref8","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3343\/alm.2012.32.2.105","article-title":"Current recommendations for laboratory testing and use of bone turnover markers in management of osteoporosis","volume":"32","author":"Lee J","year":"2012","journal-title":"Ann Lab Med"},{"issue":"8 Pt 2","key":"ref9","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1093\/clinchem\/45.8.1359","article-title":"Clinical utility of biochemical markers of bone remodeling","volume":"45","author":"Watts NB","year":"1999","journal-title":"Clin Chem"},{"issue":"7","key":"ref10","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1007\/s00198-008-0769-x","article-title":"Bone turnover markers are correlated with quantitative ultrasound of the calcaneus: 5-year longitudinal data","volume":"20","author":"Lenora J","year":"2009","journal-title":"Osteoporos Int"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S0889-8529(05)70004-9","article-title":"Pathophysiology of osteoporosis","volume":"27","author":"Heaney RP","year":"1998","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1210\/jc.2011-2081","article-title":"Low-dose zoledronate in osteopenic postmenopausal women: a randomized controlled trial","volume":"97","author":"Grey A","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"ref13","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1590\/S0004-27302013000200010","article-title":"Accelerated fracture healing with teriparatide","volume":"57","author":"Borges JLC","year":"2013","journal-title":"Arq Bras Endocrinol Metab"},{"issue":"1","key":"ref14","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1530\/EJE-11-0740","article-title":"Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study","volume":"166","author":"Jakob F","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s00198-010-1501-1","article-title":"Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards","volume":"22","author":"Vasikaran S","year":"2011","journal-title":"Osteoporos Int"},{"issue":"Pt2","key":"ref16","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1258\/acb.2011.010286","article-title":"Recommendations for bone marker standards in osteoporosis: what, why and where to now?","volume":"48","author":"Vasikaran SD","year":"2011","journal-title":"Ann Clin Biochem"},{"issue":"2","key":"ref17","first-page":"75","article-title":"Diagn\u00f3stico laboratorial e monitoramento das doen\u00e7as osteometab\u00f3licas","volume":"43","author":"Vieira JGH","year":"2007","journal-title":"J Bras Patol Med Lab"},{"issue":"Suppl 1","key":"ref18","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1186\/ar2165","article-title":"Biology of RANK, RANKL, and osteoprotegerin","volume":"9","author":"Boyce BF","year":"2007","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"ref19","first-page":"74","article-title":"[Concepts and determination of reference values for human biomonitoring of environmental contaminants]","volume":"27","author":"Kuno R","year":"2010","journal-title":"Rev Panam Salud Publica"},{"issue":"3","key":"ref20","first-page":"119","article-title":"The role of biochemical markers of bone turnover in osteoporosis management in clinical practice","volume":"27","author":"Vasikaran SD","year":"2006","journal-title":"Clin Biochem Rev"},{"issue":"8","key":"ref21","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1055\/s-0034-1374610","article-title":"Current controversies in clinical management of postmenopausal osteoporosis","volume":"122","author":"Kerschan-Schindl K","year":"2014","journal-title":"Exp Clin Endocrinol Diabetes"},{"issue":"3","key":"ref22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00198-009-0974-2","article-title":"Laboratory reproducibility of biochemical markers of bone turnover in clinical practice","volume":"21","author":"Schafer AL","year":"2010","journal-title":"Osteoporos Int"},{"issue":"6","key":"ref23","first-page":"1693","article-title":"Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment","volume":"79","author":"Garnero P","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"issue":"Pt 2","key":"ref24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1258\/acb.2011.010286","article-title":"Recommendations for bone marker standards in osteoporosis: what, why and where to now?","volume":"48","author":"Vasikaran SD","year":"2011","journal-title":"Ann Clin Biochem"},{"issue":"1","key":"ref25","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0002-9343(96)00387-7","article-title":"Hormone replacement therapy in postmenopausal women: urinary n-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density","volume":"102","author":"Chesnut 3rd CH","year":"1997","journal-title":"Am J Med"},{"issue":"3","key":"ref26","first-page":"149","article-title":"Biochemical markers in osteoporosis: usefulness in clinical practice","volume":"8","author":"Romero Barco CM","year":"2012","journal-title":"Reumatol Clin"}],"container-title":["Revista da Associa\u00e7\u00e3o M\u00e9dica Brasileira"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ramb\/v62n4\/0104-4230-ramb-62-4-0368.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,3]],"date-time":"2022-07-03T05:01:48Z","timestamp":1656824508000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0104-42302016000400368&lng=en&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7]]},"references-count":26,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,7]]}},"alternative-id":["S0104-42302016000400368"],"URL":"https:\/\/doi.org\/10.1590\/1806-9282.62.04.368","relation":{},"ISSN":["0104-4230"],"issn-type":[{"value":"0104-4230","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7]]}}}